The FDA granted Amag Pharmaceuticals Inc. approval to market Feraheme injection for intravenous use in the treatment of iron deficiency anemia in adults with chronic kidney disease. The complete treatment can be delivered with just two injections over an eight day period. Safety results from four Phase III studies of patients with chronic kidney disease and iron deficiency anemia were used in granting approval.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지